var data={"title":"Succinylcholine (suxamethonium): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Succinylcholine (suxamethonium): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6992?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">see &quot;Succinylcholine (suxamethonium): Drug information&quot;</a> and <a href=\"topic.htm?path=succinylcholine-suxamethonium-patient-drug-information\" class=\"drug drug_patient\">see &quot;Succinylcholine (suxamethonium): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709420\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of Cardiac Arrest from Hyperkalemic Rhabdomyolysis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">There have been rare reports of acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest, and death after the administration of succinylcholine to apparently healthy children who were subsequently found to have undiagnosed skeletal muscle myopathy, most frequently Duchenne muscular dystrophy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">This syndrome often presents as peaked T-waves and sudden cardiac arrest within minutes after the administration of the drug in healthy appearing children (usually, but not exclusively, males, and most frequently 8 years of age or younger). There have also been reports in adolescents.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Therefore, when a healthy appearing infant or child develops cardiac arrest soon after administration of succinylcholine not felt to be due to inadequate ventilation, oxygenation, or anesthetic overdose, immediate treatment for hyperkalemia should be instituted. This should include administration of intravenous calcium, bicarbonate, and glucose with insulin, with hyperventilation. Due to the abrupt onset of this syndrome, routine resuscitative measures are likely to be unsuccessful. However, extraordinary and prolonged resuscitative efforts have resulted in successful resuscitation in some reported cases. In addition, in the presence of signs of malignant hyperthermia, appropriate treatment should be instituted concurrently.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Since there may be no signs or symptoms to alert the practitioner to which patients are at risk, it is recommended that the use of succinylcholine in children should be reserved for emergency intubation or instances where immediate securing of the airway is necessary, such as laryngospasm, difficult airway, full stomach, or for intramuscular use when a suitable vein is inaccessible.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223430\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Anectine;</li>\n      <li>Quelicin;</li>\n      <li>Quelicin-1000 [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223431\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Quelicin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062393\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Neuromuscular Blocker Agent, Depolarizing</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Skeletal Muscle Relaxant, Paralytic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445117\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Because of the risk of adverse effects, including malignant hyperthermia and cardiac arrhythmias, surgical or long-term paralytic use (ie, continuous IV infusion) is <b>not</b> recommended (Cot&eacute; 2013; Fisher 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Endotracheal intubation:</b> <b>Note:</b> To reduce the risk of bradycardia or asystole, premedication with atropine recommended prior to IV succinylcholine doses (AAP [Hegenbarth 2008]; Choong 2010; Cot&eacute; 2013; Ghanta 2007; Lemyre 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Emergent (eg, rapid sequence intubation): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM: 4 to 5 mg/kg; pharmacokinetic data suggests that neonates typically require higher mg/kg doses than older pediatric patients (AAP [Hegenbarth 2008]; Cote 2013) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: 2 to 3 mg/kg (AAP [Hegenbarth 2008]; Cote 2013) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Nonemergent:</i> Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM: 2 mg/kg/dose; reserved for situations of no IV access (AAP [Kumar 2010]) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: 2 mg/kg/dose (Choong 2010; Ghanta 2007; Lemyre 2009); one trial allowed repeat doses of 1 mg/kg every 3 to 5 minutes if inadequate response (failed intubation attempt) up to a <b>total</b> maximum dose of 4 mg/kg (ie, 2 additional doses) (Ghanta 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062387\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">see &quot;Succinylcholine (suxamethonium): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose to effect; doses will vary due to interpatient variability. Use carefully and/or consider dose reduction in patients with reduced plasma cholinesterase activity due to genetic abnormalities of plasma cholinesterase or when associated with other conditions (eg, electrolyte abnormalities, neuromuscular disease); prolonged neuromuscular blockade may occur. Initial dose of succinylcholine must be increased when nondepolarizing agent pretreatment used because of the antagonism between succinylcholine and nondepolarizing neuromuscular-blocking agents (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Because of the risk of adverse effects including malignant hyperthermia and cardiac arrhythmias, surgical or long-term paralytic use (ie, continuous IV infusion) is not recommended (Cot&eacute; 2013; Fisher 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endotracheal intubation; emergent (eg, rapid sequence intubation): Note:</b> To reduce the risk of bradycardia or asystole, premedication with atropine recommended prior to IV succinylcholine doses (AAP [Hegenbarth 2008]; Cot&eacute; 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents: <b>Note:</b> In obese patients, pediatric patient data (age range: 9 to 15 years) suggest dosing based on use total body weight (Rose 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants &lt;6 months: Limited data available: 4 to 5 mg/kg; pharmacokinetic data suggests that young infants typically require doses on the higher end of this range (AAP [Hegenbarth 2008]; Cot&eacute; 2013) </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants &ge;6 months and Children: 4 mg/kg; maximum dose: 150 mg/dose (AAP [Hegenbarth 2008]; Lui 1981)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: 3 to 4 mg/kg; maximum dose: 150 mg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants &le;6 months: 2 to 3 mg/kg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants &gt;6 months and Children &le;2 years: 1 to 2 mg/kg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children &gt;2 years and Adolescents: 1 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate dosing: Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants: 2 to 3 mg/kg/dose (AAP [Hegenbarth 2008]; Cot&eacute; 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children: 1 to 2 mg/kg/dose (AAP [Hegenbarth 2008]; Ballow 2012; Cot&eacute; 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Adolescents: 1 to 1.5 mg/kg/dose (Ballow 2012; Sluga 2005; Weiss 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Neuromuscular blockade: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Up to 3 to 4 mg/kg, maximum dose: 150 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intubation: 0.6 mg/kg (range: 0.3 to 1.1 mg/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Long surgical procedures (intermittent administration): Initial: 0.3 to 1.1 mg/kg; administer additional doses of 0.04 to 0.07 mg/kg at appropriate intervals as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Pretreatment with atropine may reduce occurrence of bradycardia. Initial dose of succinylcholine must be increased when nondepolarizing agent pretreatment used because of the antagonism between succinylcholine and nondepolarizing neuromuscular-blocking agents (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223412\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anectine: 20 mg/mL (10 mL) [contains methylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Quelicin: 20 mg/mL (10 mL) [contains methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Quelicin-1000: 100 mg/mL (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/5 mL (5 mL); 140 mg/7 mL (7 mL); 200 mg/10 mL (10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223397\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062396\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM:  Injection should be made deeply. Use only when IV access is not available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: May be administered undiluted by rapid IV injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223426\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Manufacturer recommends refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) and may be stored at room temperature for 14 days; however, additional testing has demonstrated stability for &le;6 months unrefrigerated (25&deg;C) (Ross, 1988; Roy, 2008). Stability in polypropylene syringes (20 mg/mL) at room temperature (25&deg;C) is 45 days (Storms, 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062395\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct to anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation (FDA approved in all ages)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2973356\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:</p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">- Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">- Healthcare professionals should be on high alert (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Quelicin [U.S., Brazil, Canada, Indonesia] may be confused with Keflin brand name for cefalotin [Argentina, Brazil, Mexico, Netherlands, Norway]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223477\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia (higher with second dose; more frequent in children), cardiac arrhythmia, hypertension, hypotension, malignant hyperthermia, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperkalemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Sialorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Fasciculations, jaw tightness, myalgia (postoperative), rhabdomyolysis (with possible myoglobinuric acute renal failure)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Increased intraocular pressure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea, respiratory depression (prolonged)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal bone growth (myositis ossificans; prolonged use), myopathy (acute quadriplegic myopathy syndrome; prolonged use)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223418\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Hypersensitivity to succinylcholine or any component of the formulation; personal or familial history of malignant hyperthermia; skeletal muscle myopathies; use after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for neuromuscular blockers is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223401\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis: Severe anaphylactic reactions (some life-threatening and fatal) have been reported. Cross-sensitivity with other neuromuscular-blocking agents may occur; use extreme caution in patients with previous anaphylactic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bradycardia: Risk of bradycardia may be increased with second dose and may occur more in children. Occurrence may be reduced by pretreating with anticholinergic agents (eg, atropine).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intraocular pressure (IOP): May increase IOP; avoid use in patients in which an increase in IOP is undesirable (eg, narrow-angle glaucoma, penetrating eye injuries).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intracranial pressure: May cause a transient increase in intracranial pressure (adequate anesthetic induction prior to administration of succinylcholine will minimize this effect).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intragastric pressure: May increase intragastric pressure, which could result in regurgitation and possible aspiration of stomach contents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignant hyperthermia: Use may be associated with acute onset of malignant hyperthermia; risk may be increased with concomitant administration of volatile anesthetics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vagal tone: May increase vagal tone.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Burn injury: Use with caution in patients with extensive or severe burns; risk of hyperkalemia is increased following injury. Onset of time and duration of risk are variable, but risk is generally greatest 7 to 10 days after injury. Resistance may occur in burn patients (&ge;20% of total body surface area), usually several days after the injury, and may persist for several months after wound healing (Han 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conditions which may antagonize neuromuscular blockade: Respiratory alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, muscle trauma, and diabetes mellitus may result in antagonism of neuromuscular blockade (Greenberg 2013; Miller 2010; Murray 2002; Naguib, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conditions which may potentiate neuromuscular blockade: Electrolyte abnormalities (eg, severe hypocalcemia, severe hypokalemia, hypermagnesemia), neuromuscular diseases, metabolic acidosis, respiratory acidosis, Eaton-Lambert syndrome, and myasthenia gravis may result in potentiation of neuromuscular blockade (Greenberg 2013; Miller 2010; Naguib 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fractures/muscle spasm: Use with caution in patients with fractures or muscle spasm; initial muscle fasciculations may cause additional trauma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Use with extreme caution in patients with pre-existing hyperkalemia. Severe hyperkalemia may develop in patients with chronic abdominal infections, burn injuries, multiple trauma, extensive denervation of skeletal muscle, upper motor neuron injury, subarachnoid hemorrhage, or conditions which cause degeneration of the central and peripheral nervous system.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Plasma pseudocholinesterase disorders: Metabolized by plasma cholinesterase; use with caution (if at all) in patients suspected of being homozygous for the atypical plasma cholinesterase gene. Plasma cholinesterase activity may also be reduced by burns, anemia, decompensated heart disease, infections, malignant tumors, myxedema, pregnancy, severe hepatic or renal dysfunction, peptic ulcer, and certain medications and chemicals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly, effects and duration are more variable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: <b>[US Boxed Warning]: Use caution in children and adolescents. Acute rhabdomyolysis with hyperkalemia, ventricular arrhythmias and cardiac arrest have been reported (rarely) in children with undiagnosed skeletal muscle myopathy (eg, Duchenne muscular dystrophy); occurs soon after administration and requires immediate treatment of hyperkalemia. Prolonged resuscitation may be required. Use in children should be reserved for emergency intubation when immediate airway control is necessary (eg, laryngospasm, difficult airway, full stomach), or IM use when a suitable vein is inaccessible.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Maintenance of an adequate airway and respiratory support is critical. If possible, to avoid distress to the patient, do not administer before unconsciousness has been induced.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced personnel: Should be administered by adequately trained individuals familiar with its use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25956043\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;\">In children and adolescents, rare reports of acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest, and death have been reported in children with undiagnosed skeletal muscle myopathy, most frequently Duchenne muscular dystrophy. This syndrome presents as peaked T-waves and sudden cardiac arrest within minutes after the administration of succinylcholine. Bradycardia and rarely asystole have been reported; higher incidence in children, particularly those receiving doses &gt;1.5 mg/kg, and following repeat dosing in both children and adults. Also, if sudden cardiac arrest occurs immediately after administration of succinylcholine, consider hyperkalemia as potential etiology and manage accordingly. In neonates, some experts consider hyperkalemia a contraindication for use (AAP [Kumar 2010]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300086\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223405\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12809&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May increase the serum concentration of Succinylcholine. Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Neuromuscular-Blocking Agents may diminish the therapeutic effect of Amifampridine. Amifampridine may diminish the therapeutic effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacitracin (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bambuterol: May enhance the therapeutic effect of Succinylcholine. Bambuterol may increase the serum concentration of Succinylcholine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clindamycin (Topical): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: May increase the serum concentration of Succinylcholine. Management: Consider alternatives to succinylcholine in patients who have received cyclophosphamide in the past 10 days, or reduced succinylcholine doses (a serum pseudocholinesterase assay may help inform this reduction) with close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echothiophate Iodide: May increase the serum concentration of Succinylcholine. Management: For patients receiving echothiophate iodide eye drops, consider using a neuromuscular-blocking agents other than succinylcholine. If succinylcholine is used, consider a reduced dose, and monitor for enhanced/prolonged effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Esmolol: May enhance the neuromuscular-blocking effect of Succinylcholine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May increase the serum concentration of Succinylcholine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<b> Exceptions: </b>Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: Succinylcholine may enhance the bradycardic effect of Opioid Analgesics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenelzine: May enhance the neuromuscular-blocking effect of Succinylcholine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents. Specifically, anaphylaxis has been reported.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sertraline: May increase the serum concentration of Succinylcholine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223408\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5023968\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Small amounts cross the placenta. Sensitivity to succinylcholine may be increased due to a ~24% decrease in plasma cholinesterase activity during pregnancy and several days postpartum.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062392\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor cardiac, blood pressure, and oxygenation during administration; temperature, serum potassium and calcium, assisted ventilator status; neuromuscular function with a peripheral nerve stimulator </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223400\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Acts similar to acetylcholine, produces depolarization of the motor endplate at the myoneural junction which causes sustained flaccid skeletal muscle paralysis produced by state of accommodation that develops in adjacent excitable muscle membranes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223417\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Dependent on route, age, and dose; data suggest faster onset with higher doses (Cot&eacute; 2013): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Infants and Children: 3 to 4 minutes (Lui 1981); Adults: 2 to 3 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates and Infants: ~30 seconds (range: 19 to 40 seconds [dose: 2 to 4 mg/kg]) (Meakin 1990) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children and Adolescents: 35 to 55 seconds (Cot&eacute; 2013); Dose-specific: 40 seconds (dose: 1.5 to 2 mg/kg); 50 seconds (dose: 1 mg/kg) (Cot&eacute; 2013) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: Flaccid paralysis: &lt;60 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Dependent on route, age, and dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: 10 to 30 minutes; Observed to be shorter in infants than children </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: ~4 to 6 minutes; Faster recovery rate in infants and children compared to adults (Fisher 1975) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub> higher in neonates and infants due to larger ECF volume; higher IV doses necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Rapidly hydrolyzed by plasma pseudocholinesterase to inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~10% excreted unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323901\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Anectine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (10 mL): $23.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Quelicin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (10 mL): $23.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Succinylcholine Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (5 mL): $25.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">140 mg/7 mL (7 mL): $33.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/10 mL (10 mL): $46.94</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223420\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anectine (AE, BB, BH, BM, BS, BZ, CY, EG, ES, GB, GY, IE, IQ, IR, JM, JO, KW, LB, LY, MT, MX, OM, QA, SA, SR, SY, TT, YE);</li>\n      <li>Anekcin (PH);</li>\n      <li>Anektil (PH);</li>\n      <li>Celocurin (SE);</li>\n      <li>Celocurine (BE, FR);</li>\n      <li>Chlorsuccillin (PL);</li>\n      <li>Curacit (NO);</li>\n      <li>Curalest (NL);</li>\n      <li>Distensil (PE);</li>\n      <li>Dytylin (UA);</li>\n      <li>Ethicholine (MY, SG);</li>\n      <li>Fosfitone (AR, UY);</li>\n      <li>Leptosuccin (HR);</li>\n      <li>Lysthenon (AE, AT, BG, CH, EE, LT, LV, RO, RU, SA, TR);</li>\n      <li>Midarine (IN, JO, KW);</li>\n      <li>Mioflex (ES);</li>\n      <li>Myoplegine (LU);</li>\n      <li>Myotenlis (IT);</li>\n      <li>Neosuxa (BD);</li>\n      <li>Pantolax (DE);</li>\n      <li>Quelicin Chloride (ID, PH);</li>\n      <li>Relaxin (TW);</li>\n      <li>Scoline (IN);</li>\n      <li>Succi (AR);</li>\n      <li>Succicholine (KR);</li>\n      <li>Succinil (BR);</li>\n      <li>Succinyl Asta (HU, LU);</li>\n      <li>Succinyl Forte (IL);</li>\n      <li>Sukolin (FI, HN);</li>\n      <li>Sulax (BD);</li>\n      <li>Sumeth (PK);</li>\n      <li>Suxa (BD);</li>\n      <li>Suxamethonium (AU, NZ);</li>\n      <li>Suxameton (DK);</li>\n      <li>Suxametonio cloruro (CL);</li>\n      <li>Suxametonio Cloruro (PY);</li>\n      <li>Zuxelax (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Anectine injection solution (succinylcholine chloride) [prescribing information]. Princeton, NJ: Sandoz; April 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ballow SL, Kaups KL, Anderson S, Chang M. A standardized rapid sequence intubation protocol facilitates airway management in critically injured patients. <i>J Trauma Acute Care Surg</i>. 2012;73(6):1401-1405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/23188232 /pubmed\" target=\"_blank\" id=\"23188232 \">23188232 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choong K, AlFaleh K, Doucette J, et al. Remifentanil for endotracheal intubation in neonates: a randomised controlled trial. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2010;95(2):F80-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/20231228 /pubmed\" target=\"_blank\" id=\"20231228 \">20231228 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cook DR, Fisher CG. Neuromuscular blocking effects of succinylcholine in infants and children. <i>Anesthesiology</i>. 1975;42(6):662-665.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/1130737 /pubmed\" target=\"_blank\" id=\"1130737 \">1130737 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cot&eacute; CJ, ed. <i>A Practice of Anesthesia for Infants and Children</i>. 5th ed. Elsevier; 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fisher DM. Neuromuscular blocking agents in paediatric anaesthesia. <i>Br J Anaesth</i>. 1999;83(1):58-64. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/10616334 /pubmed\" target=\"_blank\" id=\"10616334 \">10616334 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ghanta S, Abdel-Latif ME, Lui K, Ravindranathan H, Awad J, Oei J. Propofol compared with the morphine, atropine, and suxamethonium regimen as induction agents for neonatal endotracheal intubation: a randomized, controlled trial. <i>Pediatrics</i>. 2007;119(6):e1248-1255.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/17485450 /pubmed\" target=\"_blank\" id=\"17485450 \">17485450 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? <i>Crit Care Med</i>. 2013;41(5):1332-1344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/23591211/pubmed\" target=\"_blank\" id=\"23591211\">23591211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Han TH, Martyn JA. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus. <i>Br J Anaesth</i>. 2009;102(1):55-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/19029093/pubmed\" target=\"_blank\" id=\"19029093\">19029093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA, American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/18245435 /pubmed\" target=\"_blank\" id=\"18245435 \">18245435 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar P, Denson SE, Mancuso TJ, et al, &quot;Premedication for Nonemergency Endotracheal Intubation in the Neonate,&quot; <i>Pediatrics</i>, 2010, 125(3):608-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/20176672/pubmed\" target=\"_blank\" id=\"20176672\">20176672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lemyre B, Cheng R, Gaboury I. Atropine, fentanyl and succinylcholine for non-urgent intubations in newborns. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2009;94(6):F439-442.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/19307222 /pubmed\" target=\"_blank\" id=\"19307222 \">19307222 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu LM, DeCook TH, Goudsouzian NG, Ryan JF, Liu PL. Dose response to intramuscular succinylcholine in children.<i> Anesthesiology</i>. 1981;55(5):599-602. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/7294424/pubmed\" target=\"_blank\" id=\"7294424\">7294424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meakin G, Walker RW, Dearlove OR. Myotonic and neuromuscular blocking effects of increased doses of suxamethonium in infants and children. <i>Br J Anaesth</i>. 1990;65(6):816-818.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/2265051/pubmed\" target=\"_blank\" id=\"2265051\">2265051</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, ed. Miller&rsquo;s Anesthesia, 7th ed. Philadelphia PA: Churchill Livingstone; 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray MJ, Cowen J, DeBlock H, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. <i>Crit Care Med</i>. 2002;30(1):142-156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/11902255/pubmed\" target=\"_blank\" id=\"11902255\">11902255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naguib M, Flood P, McArdle JJ, Brenner HR. Advances in neurobiology of the neuromuscular junction. Implications for the anesthesiologist. <i>Anesthesiology</i>. 2002;96(1):202-231.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/11753022/pubmed\" target=\"_blank\" id=\"11753022\">11753022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quelicin injection (succinylcholine chloride) [prescribing information]. Lake Forest, IL: Hospira; September 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rose JB, Theroux MC, and Katz MS, &ldquo;The Potency of Succinylcholine in Obese Adolescents,&rdquo; <i>Anesth Analg</i>, 2000, 90(3):576-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/10702440/pubmed\" target=\"_blank\" id=\"10702440\">10702440</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ross MB. Additional stability guidelines for routinely refrigerated drug products. <i>Am J Hosp Pharm</i>. 1988;45(7):1498-1499.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/3414714/pubmed\" target=\"_blank\" id=\"3414714\">3414714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roy JJ, Boismenu D, Mamer OA, et al. Room temperature stability of injectable succinylcholine dichloride. <i>Int J Pharm Compound</i>. 2008;12(1): 83-85.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sluga M, Ummenhofer W, Studer W, et al, &quot;Rocuronium Versus Succinylcholine for Rapid Sequence Induction of Anesthesia and Endotracheal Intubation: A Prospective, Randomized Trial in Emergent Cases,&quot; <i>Anesth Analg</i>, 2005, 101(5):1356-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/16243994/pubmed\" target=\"_blank\" id=\"16243994\">16243994</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Storms ML, Stewart JT, Warren FW. Stability of succinylcholine chloride injection at ambient temperature and 4&deg;C in polypropylene syringes. <i>Int J Pharm Compound</i>. 2003;7(1):68-70.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiss JH, Gratz I, Goldberg ME, et al, &quot;Double-Blind Comparison of Two Doses of Rocuronium and Succinylcholine for Rapid-Sequence Intubation,&quot; <i>J Clin Anesth</i>, 1997, 9(5):379-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/succinylcholine-suxamethonium-pediatric-drug-information/abstract-text/9257203/pubmed\" target=\"_blank\" id=\"9257203\">9257203</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12809 Version 117.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709420\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F223430\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F223431\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062393\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445117\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062387\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F223412\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F223397\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062396\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F223426\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062395\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2973356\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F223477\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F223418\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F223401\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25956043\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300086\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F223405\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F223408\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5023968\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062392\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F223400\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F223417\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323901\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F223420\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12809|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=succinylcholine-suxamethonium-drug-information\" class=\"drug drug_general\">Succinylcholine (suxamethonium): Drug information</a></li><li><a href=\"topic.htm?path=succinylcholine-suxamethonium-patient-drug-information\" class=\"drug drug_patient\">Succinylcholine (suxamethonium): Patient drug information</a></li></ul></div></div>","javascript":null}